Vincerx Pharma Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … Vincerx Pharma, Inc. 2020 Stock Incentive Plan (Full title of the plan) Ahmed M. Hamdy. “Over the past months, Vincerx has completed transformative milestones; licensing a compelling oncology pipeline from Bayer, launching as a public company, and strengthening our already proven leadership team,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Before founding LifeSci Advisors, LLC, and LifeSci Capital, LLC, in March 2010, Dr McDonald served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008. Since May 2018, Dr Druker has served as a member of the board of directors of Amgen Inc., a multinational biopharmaceutical company. New extended dates for the world’s largest biotech partnering experience, October 19-20, 2021 Mr Salva co-founded Acerta Pharma and served as its vice president of operations from February 2013 to November 2016. Dr Hamdy has served as a clinical advisor and member of the board of directors of Andes Biotechnologies, a nucleic acid-based drug discovery and development company, since September 2016, as a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz, since April 2019, and as a member of the Palo Alto Medical Foundation President’s Council since March 2016. In the current and next generation of black scientists and entrepreneurs. That trial is expected to begin dosing patients in Q2 of 2021, said Vincerx CEO Ahmed Hamdy. Dr Druker received a BA in chemistry from the University of California, San Diego, and an MD from the University of San Diego Medicine, San Diego. Bringing you daily news at the intersection of biotechnology, politics, patients & the planet. VINCERX, CEO AND CHAIRMAN OF THE BOARD OF DIRECTORS Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. “Over the past months, Vincerx has completed transformative milestones; licensing a compelling oncology pipeline from Bayer, launching as a public company, and strengthening our already proven leadership team,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. The SPAC, Lifesci investments (founding Partner: Andrew I. McDonald, Ph.D), led Vincerx’s NASDAQ listing after consummation of a merger agreement on December 23, 2020. MarketBeat's community ratings are surveys of what our community members think about Vincerx Pharma and other stocks. “This … “The payload is a modified camptothecin derivative which has been optimized for high cell … Ms Bushnell has served as a partner of King & Spalding LLP, a global corporate law firm, since September 2009. Biotech SPACs (special purpose acquisition companies) have reached record levels in 2020. Dr McDonald has served as chief executive officer of Attune Pharmaceuticals, a clinical-stage biotechnology company, since March 2015 and is a founding partner of LifeSci Advisors, LLC, a life sciences investor relations consultancy company, and LifeSci Capital, LLC, an emerging life sciences investment bank. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a statement. BIO Patient & Health Advocacy Digital Summit, Learn about our mission, vision, values and priorities, Find out about BIO's programs & initiatives, Meet BIO's Senior Leadership and Board of Directors, Get to know the outstanding people and companies BIO supports, VINCERX, CEO AND CHAIRMAN OF THE BOARD OF DIRECTORS. Prior to that, Dr. Hamdy co-founded … UiPath (NYSE: PATH), a leading enterprise automation software company, today announced the launch of the first automation school in Ireland to educate the next generation of the country’s workforce on automation. Ms Bushnell received an AB in psychology from Stanford University and a JD from the Georgetown University Law Center. Dr Izumi has served as Vincerx’s Chief Operations Officer and as a member Vincerx’s board of directors since March 2019. “The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Dr Stevens was a Recipient of 2019 Oregon State University, Icon of Pharmacy award, and induction into the Pharmacy Hall of Fame. Phase 1b studies in in Myc-driven hematologic malignancies and solid tumors, as well as relapsed/refractory Chronic Lymphocytic Leukemia to initiate in 1H 2021 PALO ALTO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a … Dr Hamdy received a MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt. Vincerx Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39244 83-3197402 (State or Other Jurisdiction. Vincerx Pharma, Inc. Condensed Consolidated Balance Sheets. Before founding Aspire Therapeutics, Dr Izumi served as senior director of clinical development at Pharmacyclics LLC, a biopharmaceutical company, from February 2010 to May 2011, where she worked on designing and implementing seven clinical studies across various hematologic malignancies (including three studies that garnered breakthrough therapy designation) for the first BTK inhibitor (IMBRUVICA®) to enter clinical trials. Dr Druker has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. Sign up for the Good Day BIO Newsletter >. Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021 About Vincerx Pharma, Inc.Vincerx Pharma, Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and … Dr Stevens was a founder and has served as Chief Scientific Officer and Executive Vice President of Camargo Pharmaceutical Services, LLC, a drug development consulting company, since 2003, and a member of its board of directors since March 2017. Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry. “The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. That trial is expected to begin dosing patients in Q2 of 2021, said Vincerx CEO Ahmed Hamdy. Vincerx Pharma, Inc. 260 Sheridan Avenue, Suite 400. The market is expected to surge at a CAGR of 53% and is anticipated to surpass USD 6,773 Million by 2026. Health equality in access to medicines and ensuring diversity in clinical trials. March 31, 2021. Employer Identification No.) A recent…, 1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Vincerx Pharma has received 100.00% “outperform” votes from our community. Ahmed M. Hamdy, M.D. Chief Executive Officer. “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Dr Lee received a BS in biology from Stanford University, an MD from the University of Minnesota, Twin Cities, and special training in otolaryngology-head and neck surgery from the University of Iowa. “The Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,” said Ahmed Hamdy … Vote “Underperform” if you believe VINC will underperform the S&P 500 … About Vincerx Pharma, Inc.Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … Mr Lowe holds a BS in business administration from California Polytechnic State University and an MBA from St. Mary’s University, Texas. "The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development," Hamdy said in a statement. Since July 2007, Dr Druker served as director of the Oregon Health and Science University Knight Cancer Institute. BIO now offers on-demand online classes that can be taken anywhere, anytime and at your own pace. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from February 2013 to February 2016. "The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development," Hamdy said in a statement. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a … Mr Lowe served as a director for Inspyr Therapeutics, Inc., an integrated biopharmaceutical company, from September 2016 to December 2018. Vincerx Founders 4 AHMED HAMDY, MD CEO • Cofounder of Acerta Pharma • Former CMO of Pharmacyclics, leading developer of Imbruvica® • Proven track record for assembling experienced teams that deliver from INDs to NDAs RAQUEL IZUMI, PhD COO • Cofounder of Acerta Pharma • Former Sr Director of Clinical Development of Pharmacyclics • Extensive drug … “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. December 31, 2020 (Unaudited) ASSETS. Dr Izumi was a Howard Hughes Predoctoral Fellow at the University of California, Los Angeles where she obtained a PhD in microbiology and immunology. Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. Mr Lowe also served as the Managing Partner of the Innventus Fund at Innventure, a venture capital firm, from January 2017 to March 2020 and as a member of the board of directors of Innventure from August 2016 to January 2020. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Dr Lee served as director of the cancer center of Stanford Health, a leading academic health system from July 2012 to May 2016. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in … “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Vote “Outperform” if you believe VINC will outperform the S&P 500 over the long term. We lead with respect, humanity, integrity, and inclusion. Vincerx Pharma Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Top market players in the market are Airbus S.A.S., Amazon.com, Inc., BIZZBY, Boeing, Cheetah Logistic Technology, Deutsche Post … Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021. 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker," said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Mr Lowe has served as chief financial officer of Cortexyme, Inc., a clinical-stage biopharmaceutical company, since January 2019. Dr Druker has served in various capacities at the Oregon Health and Science University, as a physician since July 1993, professor since July 2000, and associate dean of Oncology since July 2010. Interactive chart for Vincerx Pharma, Inc. (VINCW) – analyse all of the data with a huge range of indicators. wide,” said Ahmed Hamdy, CEO and cofounder of Vincerx. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in … 260 Sheridan Avenue, Suite 400 : Palo Alto, California : 94306 (Address of principal executive offices) (Zip Code) (650) 800-6676 (Registrant’s … Since September 2010, Ms Bushnell has served as a member of the board of directors of the Legal Aid Society of San Mateo County. Issuer Name and Ticker or Trading Symbol Vincera Pharma, Inc. [ VINC] 4. v? Dr. Hamdy co-founded Vincera Pharma and served as its Chief Executive Officer and as a member of its board of directors from March 2019 to December 2020. Hamdy Ahmed MD (Last) (First) (Middle) 4500 GREAT AMERICA PARKWAY, SUITE 100, #29 (Street) SANTA CLARA: CA: 95054 (City) (State) (Zip) 2. [225+ Pages Research Report] According to the recent research report; the global Drone Package Delivery Market in 2020 was approximately USD 528 Million. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Opportunities for women, Black and other minority populations in the growing Bio-economy. Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Vincerx also announced the additions of Hermes Garbán and Hans-Georg Lerchen as chief medical officer and chief scientific officer, respectively. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a statement. has served as our Chief Executive Officer and Chairman of our board of directors since December 2020, and as our President from December 2020 to January 2021. File Number) (I.R.S. Before founding Camargo Pharmaceutical Services, Dr Stevens was Senior Director of Clinical Operations at Barr Research, Inc. (formerly Duramed Pharmaceuticals, Inc.), a pharmaceutical product company, from 1999 to 2002, and served as Director of Pharmacokinetics & Scientific affairs at Phoenix International Life Sciences Inc from 1996 to 1999. Providing tools to accelerate gender, racial, ethnic and LGBTQ representation on biotech company boards, in C-suites and in functional leadership positions. Before that, Dr Izumi co-founded Acerta Pharma and served as its executive vice president of clinical development from February 2013 to May 2020. of Incorporation) (Commission. From 2004 to 2006, Dr McDonald served as head of healthcare research and a biotechnology analyst at ThinkEquity Partners, a boutique investment bank. Dr Lee served as executive director of the Chan Soon Shiong Institute of Molecular Medicine, a biomedical and translational research institute and as a full professor at the University of South Dakota, from May 2016 to September 2018 and September 2010 to May 2016, respectively. Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Before that, Dr Lee served as senior vice president of clinical development of Nantkwest, Inc., an innovative clinical-stage immunotherapy company, from May 2016 to May 2020. Before that, Mr Salva served as senior director of corporate finance at Pharmacyclics. PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and … of Incorporation) (Commission. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Vincerx’s second clinical program for potential best-in-class CDK9 inhibitor . Dr McDonald holds Series 7, 24, 63, 79, 86, and 87 licenses. File Number) (I.R.S. “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Dr McDonald received a PhD in organic chemistry from University of California, Irvine and completed his BS in chemistry at University of California, Berkeley. Dr Druker has served as a member of the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: X: … BIO Member and group discounts available! Mr Lowe served as the interim chief executive officer and chief financial officer of Hansen Medical, a medical robotics company listed on Nasdaq prior to its acquisition by Auris Surgical Robotics in 2016, from February 2014 to July 2016. “These accomplishments, in combination with our strong balance sheet, leave us well … Vincerx Pharma, Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … Dr Stevens has a Bachelor of Arts in health education from the University of Washington, Seattle, a PhD in Biopharmaceutics/Pharmacokinetics from Oregon State University and an MBA from Xavier University. Vincerx Pharma was founded by CEO Ahmed Hamdy, MD, COO Raquel Izumi, PhD, CBO Stuart Hwang, PhD, General Counsel, Tom Thomas and John Byrd, MD. Pillsbury Winthrop Shaw Pittman LLP. Current assets: Cash and cash equivalents Stockhouse.com use cookies on this site. Brian Druker, MD is a member of Vincerx’s board of directors. Dr. Ahmed M. Hamdy, who previously also held the title of President, will continue as the Company’s Chief Executive Officer and Chairman of the Board and as the Company’s principal executive officer. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. “Preclinical data for VIP152 show highly selective, ATP-independent, inhibition of … Palo Alto, CA 94306 (650) 800-6676 (Name and address of agent for service) (650) 800-6676 (Registrant’s telephone number, including area code) Copies to: Gabriella A. Lombardi, Esq. Date of Event Requiring Statement (Month/Day/Year) 12/23/2020: 3. Ms Bushnell has served as a member of the board of trustees of the University of California, Santa Cruz, Foundation since February 2015, and as chair of the Dean’s Council of the Baskin School of Engineering at the University of California, Santa Cruz, since July 2019. PALO ALTO, Calif., April 01, 2021 -- Vincerx Pharma, Inc. , a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting... | April 30, 2021 Laura Bushnell, JD is a member of Vincerx’s board of directors. From January 2015 to December 2018, Mr Lowe served as chief financial officer of Sentreheart, Inc., a biotechnology company. Mr Salva received an AB in business economics and an AB in philosophy from Brown University and a MSc in economics and philosophy form the London School of Economics. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx.